Horizon Investments LLC Sells 40,922 Shares of Sabra Healthcare REIT, Inc. $SBRA

Horizon Investments LLC lowered its holdings in Sabra Healthcare REIT, Inc. (NASDAQ:SBRA) by 52.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 37,138 shares of the real estate investment trust’s stock after selling 40,922 shares during the quarter. Horizon Investments LLC’s holdings in Sabra Healthcare REIT were worth $703,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in SBRA. Sumitomo Mitsui Trust Group Inc. boosted its position in Sabra Healthcare REIT by 1,019.8% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,005,374 shares of the real estate investment trust’s stock valued at $56,922,000 after buying an additional 2,736,993 shares in the last quarter. Balyasny Asset Management L.P. bought a new stake in shares of Sabra Healthcare REIT during the second quarter worth approximately $49,955,000. Qube Research & Technologies Ltd raised its stake in shares of Sabra Healthcare REIT by 856.5% during the second quarter. Qube Research & Technologies Ltd now owns 1,398,965 shares of the real estate investment trust’s stock worth $25,797,000 after buying an additional 1,252,708 shares during the last quarter. JPMorgan Chase & Co. raised its stake in shares of Sabra Healthcare REIT by 33.7% during the third quarter. JPMorgan Chase & Co. now owns 3,589,253 shares of the real estate investment trust’s stock worth $66,904,000 after buying an additional 903,841 shares during the last quarter. Finally, UBS Group AG increased its stake in Sabra Healthcare REIT by 143.1% in the fourth quarter. UBS Group AG now owns 1,460,219 shares of the real estate investment trust’s stock valued at $27,657,000 after purchasing an additional 859,584 shares in the last quarter. 99.40% of the stock is currently owned by institutional investors and hedge funds.

Sabra Healthcare REIT Price Performance

SBRA stock opened at $20.75 on Friday. The company has a quick ratio of 4.72, a current ratio of 4.72 and a debt-to-equity ratio of 0.96. Sabra Healthcare REIT, Inc. has a 12 month low of $17.08 and a 12 month high of $21.07. The firm has a market cap of $5.23 billion, a P/E ratio of 32.94, a P/E/G ratio of 1.65 and a beta of 0.67. The company’s 50-day moving average price is $20.24 and its two-hundred day moving average price is $19.41.

Sabra Healthcare REIT (NASDAQ:SBRA) last released its earnings results on Wednesday, April 29th. The real estate investment trust reported $0.16 EPS for the quarter, meeting the consensus estimate of $0.16. Sabra Healthcare REIT had a net margin of 19.22% and a return on equity of 5.60%. The firm had revenue of $221.75 million for the quarter, compared to analyst estimates of $209.20 million. During the same period last year, the firm earned $0.37 EPS. The business’s quarterly revenue was up 20.9% compared to the same quarter last year. Sabra Healthcare REIT has set its FY 2026 guidance at 1.550-1.590 EPS. On average, analysts anticipate that Sabra Healthcare REIT, Inc. will post 1.5 earnings per share for the current fiscal year.

Sabra Healthcare REIT Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 29th. Investors of record on Friday, May 15th will be issued a dividend of $0.30 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $1.20 annualized dividend and a dividend yield of 5.8%. Sabra Healthcare REIT’s payout ratio is 190.48%.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on SBRA shares. UBS Group upped their target price on shares of Sabra Healthcare REIT from $20.00 to $21.00 and gave the company a “neutral” rating in a research note on Thursday, February 19th. Citizens Jmp raised their target price on shares of Sabra Healthcare REIT from $22.00 to $23.00 and gave the company a “market outperform” rating in a research report on Wednesday, February 18th. Wells Fargo & Company increased their price target on shares of Sabra Healthcare REIT from $21.00 to $22.00 and gave the company an “overweight” rating in a research note on Thursday, March 26th. Scotiabank increased their price target on shares of Sabra Healthcare REIT from $20.00 to $21.00 and gave the company a “sector perform” rating in a research note on Monday, March 2nd. Finally, Citigroup raised their target price on shares of Sabra Healthcare REIT from $21.00 to $24.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Five research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.00.

Sabra Healthcare REIT Profile

Sabra Healthcare REIT, Inc (NASDAQ: SBRA) is a real estate investment trust that acquires, owns and operates net?lease healthcare properties. Its diversified portfolio spans senior housing communities, skilled nursing and rehabilitation centers, outpatient medical facilities, medical office buildings, hospitals and life science properties. Sabra structures long?term, triple?net lease agreements with healthcare operators, providing stable rental income streams while allowing tenants to focus on patient care and operational excellence.

Serving a broad spectrum of care segments, Sabra’s tenants include both regional and national providers of assisted living, independent living, memory care, post?acute rehabilitation and research and development laboratories.